aTYR PHARMA INC Payments to Acquire Marketable Securities
aTYR PHARMA INC (ATYR) reported Payments to Acquire Marketable Securities of $9.99 million for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-11.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2016-05-11
- aTYR PHARMA INC payments to acquire marketable securities for the quarter ending 2016-03-31 was $9.99M.
- aTYR PHARMA INC payments to acquire marketable securities for the quarter ending 2015-12-31 was $10.04M.
- aTYR PHARMA INC payments to acquire marketable securities for the quarter ending 2015-09-30 was $14.48M.
- aTYR PHARMA INC payments to acquire marketable securities for the quarter ending 2014-12-31 was $0.00.
- aTYR PHARMA INC payments to acquire marketable securities for fiscal 2015 was $109.44M, a 1927.89% increase from fiscal 2014.
- aTYR PHARMA INC payments to acquire marketable securities for fiscal 2014 was $5.40M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2016-03-31 | $9.99M 10-Q · filed 2016-05-11 | $20.03M derived: sum of 2 quarters · filed 2016-05-11 | $34.51M derived: sum of 3 quarters · filed 2016-05-11 | |
| 2015-12-31 | $10.04M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $24.52M derived: sum of 2 quarters · filed 2016-03-30 | $109.44M 10-K · filed 2016-03-30 | |
| 2015-09-30 | $14.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $99.41M 10-Q · filed 2015-11-10 | ||
| 2015-06-30 | $84.93M 10-Q · filed 2015-08-12 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $0.00 derived: sum of 2 quarters · filed 2016-03-30 | $0.00 derived: sum of 3 quarters · filed 2016-03-30 | $5.40M 10-K · filed 2016-03-30 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $0.00 derived: sum of 2 quarters · filed 2015-11-10 | $5.40M 10-Q · filed 2015-11-10 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | $5.40M 10-Q · filed 2015-08-12 | ||
| 2014-03-31 | $5.40M 10-Q · filed 2015-06-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |